Molecular Subtype-Guided Treatment Strategies for Cutaneous T-Cell Lymphoma A Study to Improve Clinical Outcomes and Safety for Adults Aged 18 to 75

What this Trial Is About

Researchers are investigating how using molecular subtyping and immunohistochemistry to guide treatment choices can affect patients with cutaneous T-cell lymphoma CTCL. This group of diseases involves abnormal growth of certain T cells in the skin and has challenges such as rising cases, high treatment costs, variable remission times, and recurrence. The study aims to improve treatment safety, extend clinical benefits, and reduce economic burdens by tailoring therapies based on molecular classification. Patients with confirmed CTCL will have their skin lesions analyzed using an immunohistochemistry algorithm to assign molecular subtypes. Treatment strategies will then be selected according to these subtypes, for example, interferon-based immunomodulatory therapy for TCyEM patients and retinoids for TCM-type patients. The study includes a prospective group receiving subtype-based treatments and a retrospective control group from a database of past cases with complete baseline information. Participants will be followed for up to two years, during which researchers will monitor time to next treatment, response rates, progression-free survival, and overall survival. Data will be collected on clinical benefits and long-term prognosis, as well as treatment safety. The study is observational and does not involve experimental drug administration, focusing instead on evaluating existing treatment strategies guided by molecular classification.

A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma